Search results for Neuromuscular Disorders.
Found 13 clinical studies.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With An Open-Label Extension Period To Evaluate The Efficacy And Safety Of Telitacicept In Patients With Generalized Myasthenia Gravis
- Investigator: Hani Kushlaf
- Posted Date: Sep 11, 2025
- Type of Study: Drug
A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Study To Evaluate Safety, Tolerability, Pharmacometrics, And Efficacy Of Dnth103 In Adults With Multifocal Motor Neuropathy (Momentum)
- Investigator: Hani Kushlaf
- Posted Date: Sep 11, 2025
- Type of Study: Drug
A Phase 3, Double-Blind, Placebo-Controlled Study Evaluating Efficacy And Safety Of Riliprubart In Participants With Refractory Chronic Inflammatory Demyelinating Polyneuropathy
- Investigator: Hani Kushlaf
- Posted Date: Sep 11, 2025
- Type of Study: Drug
A Phase 3, Randomized, Double-Blind, Study Evaluating Efficacy And Safety Of Riliprubart Versus Intravenous Immunoglobulin (Ivig) In Participants With Chronic Inflammatory Demyelinating Polyneuropathy
- Investigator: Hani Kushlaf
- Posted Date: Sep 11, 2025
- Type of Study: Drug
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating The Efficacy And Safety Of Empasiprubart Versus Intravenous Immunoglobulin In Adults With Multifocal Motor Neuropathy
- Investigator: Hani Kushlaf
- Posted Date: Sep 10, 2025
- Type of Study: Drug
A Randomized, Double-Blind, Placebo-Controlled Phase III Study To Evaluate The Efficacy, Safety, And Tolerability Of Remibrutinib In Patients With Generalized Myasthenia Gravis, Followed By An Open-Label Extension Phase
- Investigator: Hani Kushlaf
- Posted Date: Sep 10, 2025
- Type of Study: Drug
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of Dnth103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (Captivate)
- Investigator: Hani Kushlaf
- Posted Date: Sep 10, 2025
- Type of Study: Drug
A Phase 2, Randomized, Double-Blind, Four-Arm, Placebo-Controlled, Multicenter Study Assessing The Efficacy, Safety And Tolerability Of Three Doses Of Orally Administered Bms-986368, A Faah/Mgll Inhibitor, For The Treatment Of Spasticity In Participants W
- Investigator: Shahla Hosseini
- Posted Date: Apr 30, 2025
- Type of Study: Drug
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel Group Study Of Vhb937 In Amyotrophic Lateral Sclerosis (Als) Over 40 Weeks Followed By An Open-Label Extension (Astrals)
- Investigator: Hani Kushlaf
- Posted Date: Mar 5, 2025
- Type of Study: Drug
A Post-Authorization Study To Assess Long-Term Safety In Patients With Pompe Disease Treated With Avalglucosidase Alfa
- Investigator: Hani Kushlaf
- Posted Date: Mar 5, 2025
- Type of Study: Observational/Survey
A Phase 3 Randomized, Double-Blind, Placebo- Controlled, Global Study To Evaluate The Efficacy And Safety Of Intravenous Aoc 1001 For The Treatment Of Myotonic Dystrophy Type 1
- Investigator: Hani Kushlaf
- Posted Date: Nov 7, 2024
- Type of Study: Drug
The Helping Children With Loss Instrument (Hcwl-I): Instrument Development And Validation For Construct Validity Of The Treatment
- Investigator: Rachael Nolan
- Posted Date: Jul 28, 2022
- Type of Study: Observational/Survey
Efficacy And Safety Of Pozelimab And Cemdisiran Combination Therapy In Patients With Symptomatic Generalized Myasthenia Gravis
- Investigator: Hani Kushlaf
- Posted Date: Nov 12, 2021
- Type of Study: Drug